CN107936122A - A kind of slow virus and its preparation method and application - Google Patents
A kind of slow virus and its preparation method and application Download PDFInfo
- Publication number
- CN107936122A CN107936122A CN201711481042.1A CN201711481042A CN107936122A CN 107936122 A CN107936122 A CN 107936122A CN 201711481042 A CN201711481042 A CN 201711481042A CN 107936122 A CN107936122 A CN 107936122A
- Authority
- CN
- China
- Prior art keywords
- slow virus
- carrier
- nucleotide sequence
- glycoprotein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a kind of slow virus and preparation method thereof, the slow virus after birth glycoprotein of the slow virus is modified with element S in element G upstreams;Wherein, the element S is the auxilin element of specific recognition NK cell membrane surface proteins, and the element G is the protein component derived from wild type slow virus envelope glycoprotein.The single-chain antibody that the present invention passes through the anti-NK cell surface molecules CD56 of modified specificity identification NK cells on slow virus envelope glycoprotein, it can be combined with the CD56 molecules of the NK cell surfaces infected, furthered the distance of virion and NK cells, film fusion is promoted, improves slow virus infect efficiency.
Description
Technical field
The invention belongs to biological technical field, is related to a kind of slow virus and its preparation method and application, more particularly to a kind of
It is used to prepare slow virus of CAR-NK cells and its preparation method and application.
Background technology
Chimeric antigen receptor T cell immunotherapy (Chimeric Antigen Receptor T-Cell
Immunotherapy, CAR-T) it is one of tumour adoptive immunotherapy technology of greatest concern in recent years, mainly by T
Cell surface expression Chimeric antigen receptor, carries out the identification and killing of cancer cell antigen.CAR-T immunotherapies are in multiple clinics
Experiment, especially blood bome tumor treatment in achieve significant effect.According to the report, by CAR-T immunotherapies, 90% urgency
Property lymphocytic leukemia patient obtains complete incidence graph (S.L.Maude et al.Chimeric antigen receptor T
cells for sustained remissions in leukemia.Engl.J.Med.,371,1507-1517(2014))。
But CAR-T immunotherapies be faced with cytokine storm, undershooting-effect, to solid tumor without significant curative effect the problems such as.
NK cells are the lymphocytes to tumour cell with strong lethal effect of a kind of non-MHC dependences, are mainly passed through
The intersection regulation and control of cell surface activation acceptor and Inhibitory receptor carry out the identification of tumour cell.When NK cell recognition tumours are thin
After born of the same parents, by discharging perforin and granzyme element, the apoptosis of expression film TNF family molecule inducing target cells.However, tumor patient
Internal NK cell quantities are limited, lethal effect is weaker, and there are escape mechanism for tumour so that the antitumor action of NK cells
It cannot be not fully exerted.
The effect for the NK cell killing tumour cells that CAR molecular modifications are significantly increased in NK cell surfaces.It is existing at present
Numerous studies design the CAR-NK for different tumor targets, and are carrying out clinical trial.CAR-NK has the following advantages:
Cytokine storm side reaction is small, and graft versus host disease(GVH disease) does not occur, and life cycle is short, safe.Existing CAR-NK skills
There is also defect for art:It is less efficient to be used to prepare the slow-virus infection of NK cells, only 10% or so.It is mainly rich by screening at present
Collect to improve the content of CAR-NK positive cells, but be the increase in the triviality and cost of method.
Therefore it provides a kind of slow virus with efficient infection ability, is used to prepare CAR-NK cells, is controlled in tumour immunity
Treatment field is of great significance.
The content of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of slow virus and its preparation method and application, the slow disease of preparation
Poison has the ability for efficiently infecting NK cells, simplifies the preparation process of CAR-NK cells, reduces immunization therapy cost.
For this purpose, the present invention uses following technical scheme:
In a first aspect, the present invention provides a kind of slow virus after birth glycoprotein, the slow virus after birth glycoprotein is in element G
Upstream is modified with element S;
Wherein, the element S is the auxilin element of specific recognition NK cell membrane surface proteins, and the element G is
Protein component derived from wild type slow virus envelope glycoprotein.
Peplos is wrapped around one layer of coating outside virus protein capsid, is mainly derived from host cell membrane, but
Comprising the viral glycoprotein of itself, major function is to assist cell entry host cell.The glycoprotein of envelope membrane surface identifies first
And host cell surface receptor is combined, subsequent peplos and host cell film combination, last viral capsid and viral genome
Into host cell, course of infection is completed.The present invention passes through the modified specificity identification NK cells on slow virus envelope glycoprotein
Auxilin element, the distance of furthered virion and NK cells, promotes film fusion, improves slow virus and infect effect
Rate.
Preferably, it is connecting element G's and element S that the slow virus after birth glycoprotein, which further includes element L, the element L,
Connect peptide.
Preferably, the element S is anti-CD56 single-chain antibodies.
Preferably, the element S is with histidine-tagged.
The anti-NK cell surface molecules CD56 of present invention modified specificity identification NK cells on slow virus envelope glycoprotein
Single-chain antibody (single chain antibody fragment, scFv), can be with the NK cell surfaces infected
CD56 molecules combine, and the distance of furthered virion and NK cells, promotes film fusion, improve slow virus infect efficiency.
Preferably, the nucleotide sequence of the element S is as shown in SEQ ID NO.1;
Nucleotide sequence shown in the SEQ ID NO.1 is:
CATCATCATCATCATCATCAAGTACAGCTCCAACAGTCAGGACCCGGTCTCGTTAAACCTTCCCAAACGCTGTCCCT
CACTTGCGCCATCAGCGGAGATTCCGTGAGCTCTAACTCTGCCGCTTGGAACTGGATTAGGCAATCCCCCTCCCGAG
GACTGGAATGGCTGGGAAGAACTTACTACCGCTCCAAATGGTACAACGACTACGCAGTGTCCGTCAAGTCTCGAATC
ACTATCAACCCTGACACAAGCAAAAATCAGTTTTCCCTGCAACTCAACTCAGTCACCCCTGAGGACACGGCGGTTTA
CTATTGCGCTAGAGAGAATATTGCCGCATGGACCTGGGCGTTCGATATATGGGGTCAGGGAACAATGGTAACCGTCA
GCTCCGGCGGCGGCGGATCTGGAGGTGGTGGCTCAGGTGGCGGAGGCTCCGAAATCGTTATGACACAGTCCCCTGGA
ACACTCTCCCTGTCTCCTGGTGAAAGAGCTACTCTGTCCTGCCGCGCTAGTCAATCCGTATCCTCCTCCTACCTTGC
TTGGTACCAACAAAAGCCCGGACTTGCCCCACGCCTCCTTATTTACGACACCTCACTCCGCGCAACAGATATCCCAG
ATAGATTCTCCGGATCAGGCTCCGGGACCGCTTTTACACTGACAATTTCTAGGCTCGAACCAGAGGACTTCGCTGTA
TATTACTGCCAACAGTATGGCTCTTCACCAACATTCGGACAAGGCACCAAAGTCGAAATCAAACGCACCGTAGCC.
Preferably, the element L is flexible peptide.
Preferably, the nucleotide sequence of the flexible peptide is as shown in SEQ ID NO.2;
Nucleotide sequence shown in the SEQ ID NO.2 is:
GGAGGCGGTTCAGGAGGTGGCTCGAGCGGAGGCGGTTCA.
Preferably, the element G is any one in VSV-G, RD114, BaEv or MLV or at least two combination.
In the present invention, the VSV-G is vesicular stomatitis virus glycoprotein G, and the RD114 is endogenous feline viral bag
Membrane glycoprotein, the BaEv are baboon endogenous retrovirus envelope glycoprotein, and the MLV is murine leukemia virus coating sugar
Albumen.
Second aspect, the present invention provides a kind of nucleic acid sequence for encoding slow virus after birth glycoprotein as described in relation to the first aspect
Row.
The third aspect, the present invention provides a kind of carrier, the carrier includes the nucleotide sequence as described in second aspect.
Preferably, the carrier is pMD2.G.
Preferably, the nucleotide sequence of the carrier is as shown in SEQ ID NO.3.
Fourth aspect, the present invention provides a kind of slow virus, the slow virus is imported just like the carrier described in the third aspect,
The slow virus after birth glycoprotein of expression as described in relation to the first aspect.
5th aspect, the present invention provides a kind of method for preparing the slow virus as described in fourth aspect, including following step
Suddenly:
(1) carrier of the structure as described in the third aspect;
(2) by the carrier described in step (1) and packaging plasmid cotransfection mammalian cell, viral packaging is carried out.
Preferably, the method for step (1) described structure is the nucleotide sequence as described in second aspect is inserted into pMD2.G
Between HindIII and AdeI restriction enzyme sites, structure obtains the carrier.
Preferably, step (2) described mammalian cell is 293T cells.
As optimal technical scheme, the present invention provides a kind of method for preparing the slow virus as described in fourth aspect, bag
Include following steps:
(1) nucleotide sequence as described in second aspect is inserted between HindIII the and AdeI restriction enzyme sites of pMD2.G, structure
Build to obtain the carrier;
(2) by the carrier described in step (1) and packaging plasmid cotransfection 293T cells, viral packaging is carried out.
6th aspect, the present invention provides a kind of pharmaceutical composition, described pharmaceutical composition is included as described in relation to the first aspect
Slow virus after birth glycoprotein, the nucleotide sequence as described in second aspect, the carrier as described in the third aspect or such as fourth aspect
In the slow virus any one or at least two combination.
Preferably, described pharmaceutical composition further includes any in pharmaceutically acceptable carrier, excipient or diluent
It is a kind of or at least two combination.
7th aspect, is used to prepare T cell the present invention provides a kind of pharmaceutical composition as described in terms of the 6th and is immunized
The medicine of therapy for tumor.
Compared with prior art, the present invention has the advantages that:
(1) the anti-NK cell surfaces point that the present invention passes through the modified specificity identification NK cells on slow virus envelope glycoprotein
The single-chain antibody of sub- CD56, can be combined with the CD56 molecules of the NK cell surfaces infected;
(2) slow virus envelope glycoprotein of the invention has furthered the distance of virion and NK cells, promotes film fusion,
Slow virus infect efficiency is improved, obtained slow virus infects the efficiency of NK cells up to more than 80%.
Brief description of the drawings
Fig. 1 (A) is the electrophoretogram of the SEQ ID NO.3 sequences added with a segment signal peptide sequence, and Fig. 1 (B) is pMD2.G
The electrophoretogram of nucleic acid fragments of the upper restriction enzyme site HindIII to insertion point, Fig. 1 (C) are insertion point on pMD2.G to digestion
The electrophoretogram of the nucleic acid fragment of site Adel, Fig. 1 (D) are the electrophoretogram of fusion product, and Fig. 1 (E) is the pMD2.G's after digestion
Electrophoretogram, Fig. 1 (F) they are anti-CD56-VSVG-pMD2.G carrier digestion products electrophoretograms, wherein, M is DNA standard molecular weights,
Be followed successively by from bottom to top 100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 700bp, 800bp, 900bp, 1000bp,
1200bp, 1500bp, 2000bp, 2500bp, 3000bp, 3500bp, 4000bp, 5000bp, 6000bp, 8000bp and
The molecular weight of 10000bp;
Fig. 2 (A) is the sequencing result of anti-CD56-VSVG-pMD2.G carriers 1-248bp, and Fig. 2 (B) is anti-CD56-
The sequencing result of VSVG-pMD2.G carriers 249-496bp, Fig. 2 (C) are anti-CD56-VSVG-pMD2.G carriers 497-682bp
Sequencing result, Fig. 2 (D) be anti-CD56-VSVG-pMD2.G carriers 683-882bp sequencing result;
Fig. 3 is the structure schematic diagram of slow virus after birth glycoprotein;
Fig. 4 is the structure diagram of anti-CD56-VSVG-pMD2.G carriers;
Fig. 5 is lentiviral particle protein immunoblot result figure, wherein, 1-anti-CD56-VSVG-pMD2.G carrier eggs
White immunoblot results figure, the wild VSVG-pMD2.G carrier proteins immunoblot results figures of 2-;
Fig. 6 is the infect efficiency figure that slow virus infects NK cells.
Embodiment
The technological means and its effect taken for the present invention is further explained, with reference to embodiments with attached drawing to this hair
It is bright to be further described.It is understood that the specific embodiments described herein are used only for explaining the present invention, rather than
Limitation of the invention.
In the examples where no specific technique or condition is specified, according to the described technology of document in the art or condition,
Or carried out according to product description.Reagents or instruments used without specified manufacturer, be can be by regular channel commercially available from
The conventional products of acquisition.
Material:
PCR purification kits (Shanghai life work biology);
Gel reclaims kit (Shanghai life work biology);
HindIII enzymes (Thermo Scientific);
AdeI enzymes (Thermo Scientific);
T4DNA ligases (Thermo Scientific).
The structure of 1 slow virus envelope vector anti-CD56-VSVG-pMD2.G of embodiment
(1) synthesis is added with a segment signal peptide sequence (SEQ ID NO.4 at 5' ends:TTTATTCATTGGGGTGAATTGC)
Coding slow virus after birth glycoprotein nucleotide sequence, shown in length 829bp, electrophoresis result such as Fig. 1 (A), purpose fragment length
Spend for 829bp;
(2) restriction enzyme site is expanded according to the requirement of the sequence of carrier pMD2.G and insertion point, design primer respectively
HindIII to insertion point nucleic acid fragment and insertion point to the nucleic acid fragment of restriction enzyme site AdeI, primer sequence is shown in Table 1:
1 PCR primer of table
1. the system of PCR amplification restriction enzyme site HindIII to the nucleic acid fragment of insertion point is shown in Table 2, program for 95 DEG C/
3min, (95 DEG C/20s, 45 DEG C/22s, 72 DEG C/35s) 20 circulations, 72 DEG C/5min, the electrophoresis result of PCR product is shown in Fig. 1
(B), purpose fragment length is 641bp;
2 restriction enzyme site HindIII of table to the nucleic acid fragment of insertion point PCR system
Title | Volume |
10 × pfu buffer solutions | 5μL |
dNTP | 1μL |
Primer1(SEQ ID NO.5) | 2μL |
Primer2(SEQ ID NO.6) | 2μL |
pMD2.G | 1μL |
Pfu enzymes | 0.5μL(5U/μL) |
ddH2O | Polishing is to 50 μ L |
2. the system of PCR amplification insertion point to the nucleic acid fragment of restriction enzyme site Adel is shown in Table 3, program is 95 DEG C/3min,
(95 DEG C/20s, 48 DEG C/22s, 72 DEG C/30s) 20 circulations, 72 DEG C/5min, the electrophoresis result of PCR product is shown in Fig. 1 (C), purpose
Fragment length is 440bp;
3 insertion point of table to the nucleic acid fragment of restriction enzyme site Adel PCR system
3. PCR, which merges restriction enzyme site HindIII, is added with SEQ ID to the nucleic acid fragment (fragment 1) of insertion point, 5' ends
NO.4 coding slow virus after birth glycoprotein nucleotide sequence (fragment 2) and insertion point to restriction enzyme site AdeI nucleic acid fragment
(fragment 3), fusion system are shown in Table 4, and program is 95 DEG C/3min, (95 DEG C/20s, 55 DEG C/22s, 72 DEG C/120s) 22 circulations,
72 DEG C/5min, the electrophoresis result of fusion product is shown in Fig. 1 (D), and purpose fragment length is 1850bp;
4 PCR fusion systems of table
Title | Volume |
10 × pfu buffer solutions | 5μL |
dNTP | 1μL |
Primer1(SEQ ID NO.5) | 2μL |
Primer4(SEQ ID NO.8) | 2μL |
Fragment 1 | 1μL |
Fragment 2 | 1μL |
Fragment 3 | 1μL |
Pfu enzymes | 0.5μL(5U/μL) |
ddH2O | Polishing is to 50 μ L |
4. using PCR purification kits gel recycling PCR fusion products, fusion is produced using HindIII enzymes and AdeI enzymes
Thing carries out double digestion, and digestion system is shown in Table 5, and system is put into 37 DEG C of isothermal reaction 2h in PCR instrument;
5 fusion product digestion system of table
Title | Volume |
Fusion product | 1μg |
10 × FD buffer solutions | 5μL |
HindIII enzymes | 1μL(10U/μL) |
AdeI enzymes | 1μL(10U/μL) |
ddH2O | Polishing is to 50 μ L |
5. carrying out double digestion to pMD2.G using HindIII enzymes and AdeI enzymes, digestion system is shown in Table 6, and system is put into PCR instrument
In 37 DEG C of isothermal reaction 2h, the electrooptical structure of the pMD2.G after digestion is shown in Fig. 1 (E), there is the fragment that two length do not wait, using solidifying
The big digestion pMD2.G (4.8kb) of plastic recovery kit recycling fragment;
6 pMD2.G digestion systems of table
Title | Volume |
pMD2.G | 1μg |
10 × FD buffer solutions | 5μL |
HindIII enzymes | 1μL(10U/μL) |
AdeI enzymes | 1μL(10U/μL) |
ddH2O | Polishing is to 50 μ L |
6. connecting the fusion product and pMD2.G of digestion, linked system is shown in Table 7, and it is anti-that system is put into 16 DEG C of constant temperature in PCR instrument
2h is answered, obtains connection product;
7 linked system of table
Title | Volume |
The pMD2.G of digestion | 4μL |
The fusion product of digestion | 10μL |
10 × T4DNA ligase buffer solutions | 2μL |
T4DNA ligases | 1μL(5U/μL) |
ddH2O | Polishing is to 20 μ L |
(3) 10 μ L connection products are drawn, are converted using 42 DEG C of heat shock methods, competence bacterial strain XL10-Gold, tablet
It is incubated overnight after coating in 37 DEG C of incubators;Single bacterium after picking conversion is fallen within test tube, 37 DEG C, 220rpm/min cultivated
At night, extract carrier, and carrier identification is carried out using double digestion, and sequencing identification is carried out to recombinant vector, digestion the result is shown in Figure 1 (F),
Two bar segments that length is respectively 1430bp and 5.2kb are obtained, illustrate the success of anti-CD56-VSVG-pMD2.G vector constructions,
The sequencing result of carrier is shown in Fig. 2 (A)-Fig. 2 (D).
The structure diagram of the slow virus envelope glycoprotein of restructuring is as shown in Figure 3;Anti-CD56-VSVG-pMD2.G carriers
Structure diagram it is as shown in Figure 4.
2 slow virus of embodiment is packed and verification
(1) 24h before transfection, 293T cells are passed on according to packaging quantity, according to 24 it is small when after can reach 70-
The density of 80% degrees of fusion is inoculated with;
(2) it is using coprecipitation of calcium phosphate infection protocol that anti-CD56-VSVG-pMD2.G vector introductions is thin to 293T after 24h
Born of the same parents, cell culture medium is changed to fresh DMEM high glucose mediums by 2h before transfection, and the preparation method of transfection liquid is:To 15mL from
The anti-CD56-VSVG-pMD2.G carriers of preparation and the mixed liquor of packaging plasmid, the CaCl with respective volume are added in heart pipe2
It is uniformly mixed obtained CaCl2- DNA mixed liquors, incubate 5-10min at room temperature, and slowly frothing to add in BBS liquid dropwise mixes, room
Temperature is lower to incubate 20-30min, obtains transfection liquid;
(3) transfection liquid is added dropwise in the nutrient solution of 293T cells, continues to cultivate 4-6h after mixing, it is clear with PBS after 4-6h
Wash 1-2 times, be changed to the DMEM culture mediums containing 10% hyclone, 1640 cultures containing 5% hyclone are changed to after 16h
Base, 4 DEG C of preservations of supernatant are collected after 24h, 1640 culture mediums containing 5% hyclone is changed to, is collected after 24h according to cell state
Supernatant, concentrating virus liquid;
(4) virus liquid is centrifuged into 10min with 400g at 4 DEG C, takes supernatant, supernatant is filtered by 0.45 μm of PVDF
Film, centrifuges 90min under 4 DEG C of bars, it can be seen that viral pellet, abandons supernatant, according to virus liquid initial volume, with 1 with 20000g:100
Ratio, dissolved and precipitated with appropriate PBS, and is transferred in 1.5mL centrifuge tubes;
(5) virus liquid in centrifuge tube is centrifuged into 5min with 500g, takes supernatant, dispense virus liquid, directly used or shift
Saved backup to -80 DEG C of refrigerators.
Protein immunoblot (western blot) detection is carried out to the lentiviral particle of harvest, the result is shown in Fig. 5, it is seen that warp
The slow virus that anti-CD56-VSVG-pMD2.G carriers obtain can be with normal expression histidine (His) label protein.
3 slow-virus infection NK cells of embodiment
NK cells are obtained using trophocyte cultivation cellar culture, positive rate is up to more than 95%.
Follow the steps below NK cell infections:
(1) the NK cells of acquisition are resuspended using GT-T561 culture mediums, density is 2 × 106/mL;
(2) 12 orifice plates are inoculated into the density in 1mL/ holes, add 200 μ l virus liquids, 37 DEG C, 5%CO28h is cultivated, is added
Isometric GT-T561 culture mediums containing 2% autoserum and 400U/mL IL-2, continue culture to 24h;
(3) the GT-T561 culture mediums containing 1% autoserum and 200U/mL IL-2 are replaced medium to, with 1 × 106/mL
Density inoculation continue culture to 48h.
Collect metainfective cell and carry out FCM analysis, the results are shown in Figure 6, slow virus of the invention, due to slow
Viral after birth glycoprotein is modified with anti-CD56 single-chain antibodies, compared with wild type slow virus, there is higher to infect NK cells
Efficiency, infect efficiency is up to more than 80%.
In conclusion anti-NK cell of the present invention by the modified specificity identification NK cells on slow virus envelope glycoprotein
The single-chain antibody of surface molecular CD56, can be combined, furthered virion with the CD56 molecules of the NK cell surfaces infected
With the distance of NK cells, film fusion is promoted, improves slow virus infect efficiency, obtained slow virus infects the efficiency of NK cells
Up to more than 80%.
Applicant states that the present invention illustrates the method detailed of the present invention, but not office of the invention by above-described embodiment
It is limited to above-mentioned method detailed, that is, does not mean that the present invention has to rely on above-mentioned method detailed and could implement.Technical field
Technical staff it will be clearly understood that any improvement in the present invention, equivalence replacement and auxiliary element to each raw material of product of the present invention
Addition, selection of concrete mode etc., all fall within protection scope of the present invention and the open scope.
Sequence table
<110>Hua Long Bioisystech Co., Ltd of Henan Province
<120>A kind of slow virus and its preparation method and application
<130> 20171228
<141> 2017-12-29
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 768
<212> DNA
<213>Artificial synthesized ()
<400> 1
catcatcatc atcatcatca agtacagctc caacagtcag gacccggtct cgttaaacct 60
tcccaaacgc tgtccctcac ttgcgccatc agcggagatt ccgtgagctc taactctgcc 120
gcttggaact ggattaggca atccccctcc cgaggactgg aatggctggg aagaacttac 180
taccgctcca aatggtacaa cgactacgca gtgtccgtca agtctcgaat cactatcaac 240
cctgacacaa gcaaaaatca gttttccctg caactcaact cagtcacccc tgaggacacg 300
gcggtttact attgcgctag agagaatatt gccgcatgga cctgggcgtt cgatatatgg 360
ggtcagggaa caatggtaac cgtcagctcc ggcggcggcg gatctggagg tggtggctca 420
ggtggcggag gctccgaaat cgttatgaca cagtcccctg gaacactctc cctgtctcct 480
ggtgaaagag ctactctgtc ctgccgcgct agtcaatccg tatcctcctc ctaccttgct 540
tggtaccaac aaaagcccgg acttgcccca cgcctcctta tttacgacac ctcactccgc 600
gcaacagata tcccagatag attctccgga tcaggctccg ggaccgcttt tacactgaca 660
atttctaggc tcgaaccaga ggacttcgct gtatattact gccaacagta tggctcttca 720
ccaacattcg gacaaggcac caaagtcgaa atcaaacgca ccgtagcc 768
<210> 2
<211> 39
<212> DNA
<213>Artificial synthesized ()
<400> 2
ggaggcggtt caggaggtgg ctcgagcgga ggcggttca 39
<210> 3
<211> 6629
<212> DNA
<213>Artificial synthesized ()
<400> 3
gattctgcct aataaaaaac atttattttc attgcaatga tgtatttaaa ttatttctga 60
atattttact aaaaagggaa tgtgggaggt cagtgcattt aaaacataaa gaaatgaaga 120
gctagttcaa accttgggaa aatacactat atcttaaact ccatgaaaga aggtgaggct 180
gcaaacagct aatgcacatt ggcaacagcc cctgatgcct atgccttatt catccctcag 240
aaaaggattc aagtagaggc ttgatttgga ggttaaagtt ttgctatgct gtattttaca 300
ttacttattg ttttagctgt cctcatgaat gtcttttcac tacccatttg cttatcctgc 360
atctctcagc cttgactcca ctcagttctc ttgcttagag ataccacctt tcccctgaag 420
tgttccttcc atgttttacg gcgagatggt ttctcctcgc ctggccactc agccttagtt 480
gtctctgttg tcttatagag gtctacttga agaaggaaaa acagggggca tggtttgact 540
gtcctgtgag cccttcttcc ctgcctcccc cactcacagt gacccggaat ccctcgacat 600
ggcagtctag cactagtgcg gccgcagatc tgcttcctcg ctcactgact cgctgcgctc 660
ggtcgttcgg ctgcggcgag cggtatcagc tcactcaaag gcggtaatac ggttatccac 720
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 780
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca 840
caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 900
gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 960
cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta 1020
tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 1080
gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga 1140
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 1200
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg 1260
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 1320
caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 1380
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa 1440
cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat 1500
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 1560
tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 1620
atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 1680
tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 1740
aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc 1800
catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt 1860
gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 1920
ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa 1980
aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt 2040
atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 2100
cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta tgcggcgacc 2160
gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa 2220
agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 2280
gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 2340
caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag 2400
ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 2460
tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 2520
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtggatcccc tgagggggcc 2580
cccatgggct agaggatccg gcctcggcct ctgcataaat aaaaaaaatt agtcagccat 2640
gagcttggcc cattgcatac gttgtatcca tatcataata tgtacattta tattggctca 2700
tgtccaacat taccgccatg ttgacattga ttattgacta gttattaata gtaatcaatt 2760
acggggtcat tagttcatag cccatatatg gagttccgcg ttacataact tacggtaaat 2820
ggcccgcctg gctgaccgcc caacgacccc cgcccattga cgtcaataat gacgtatgtt 2880
cccatagtaa cgccaatagg gactttccat tgacgtcaat gggtggagta tttacggtaa 2940
actgcccact tggcagtaca tcaagtgtat catatgccaa gtacgccccc tattgacgtc 3000
aatgacggta aatggcccgc ctggcattat gcccagtaca tgaccttatg ggactttcct 3060
acttggcagt acatctacgt attagtcatc gctattacca tggtgatgcg gttttggcag 3120
tacatcaatg ggcgtggata gcggtttgac tcacggggat ttccaagtct ccaccccatt 3180
gacgtcaatg ggagtttgtt ttggcaccaa aatcaacggg actttccaaa atgtcgtaac 3240
aactccgccc cattgacgca aatgggcggt aggcgtgtac ggtgggaggt ctatataagc 3300
agagctcgtt tagtgaaccg tcagatcgcc tggagacgcc atccacgctg ttttgacctc 3360
catagaagac accgggaccg atccagcctc ccctcgaagc ttacatgtgg taccgagctc 3420
ggatcctgag aacttcaggg tgagtctatg ggacccttga tgttttcttt ccccttcttt 3480
tctatggtta agttcatgtc ataggaaggg gagaagtaac agggtacaca tattgaccaa 3540
atcagggtaa ttttgcattt gtaattttaa aaaatgcttt cttcttttaa tatacttttt 3600
tgtttatctt atttctaata ctttccctaa tctctttctt tcagggcaat aatgatacaa 3660
tgtatcatgc ctctttgcac cattctaaag aataacagtg ataatttctg ggttaaggca 3720
atagcaatat ttctgcatat aaatatttct gcatataaat tgtaactgat gtaagaggtt 3780
tcatattgct aatagcagct acaatccagc taccattctg cttttatttt atggttggga 3840
taaggctgga ttattctgag tccaagctag gcccttttgc taatcatgtt catacctctt 3900
atcttcctcc cacagctcct gggcaacgtg ctggtctgtg tgctggccca tcactttggc 3960
aaagcacgtg agatctgaat tctgacacta tgaagtgcct tttgtactta gcctttttat 4020
tcattggggt gaattgccat catcatcatc atcatcaagt acagctccaa cagtcaggac 4080
ccggtctcgt taaaccttcc caaacgctgt ccctcacttg cgccatcagc ggagattccg 4140
tgagctctaa ctctgccgct tggaactgga ttaggcaatc cccctcccga ggactggaat 4200
ggctgggaag aacttactac cgctccaaat ggtacaacga ctacgcagtg tccgtcaagt 4260
ctcgaatcac tatcaaccct gacacaagca aaaatcagtt ttccctgcaa ctcaactcag 4320
tcacccctga ggacacggcg gtttactatt gcgctagaga gaatattgcc gcatggacct 4380
gggcgttcga tatatggggt cagggaacaa tggtaaccgt cagctccggc ggcggcggat 4440
ctggaggtgg tggctcaggt ggcggaggct ccgaaatcgt tatgacacag tcccctggaa 4500
cactctccct gtctcctggt gaaagagcta ctctgtcctg ccgcgctagt caatccgtat 4560
cctcctccta ccttgcttgg taccaacaaa agcccggact tgccccacgc ctccttattt 4620
acgacacctc actccgcgca acagatatcc cagatagatt ctccggatca ggctccggga 4680
ccgcttttac actgacaatt tctaggctcg aaccagagga cttcgctgta tattactgcc 4740
aacagtatgg ctcttcacca acattcggac aaggcaccaa agtcgaaatc aaacgcaccg 4800
tagccggagg cggttcagga ggtggctcga gcggaggcgg ttcaaagttc accatagttt 4860
ttccacacaa ccaaaaagga aactggaaaa atgttccttc taattaccat tattgcccgt 4920
caagctcaga tttaaattgg cataatgact taataggcac agccttacaa gtcaaaatgc 4980
ccaagagtca caaggctatt caagcagacg gttggatgtg tcatgcttcc aaatgggtca 5040
ctacttgtga tttccgctgg tatggaccga agtatataac acattccatc cgatccttca 5100
ctccatctgt agaacaatgc aaggaaagca ttgaacaaac gaaacaagga acttggctga 5160
atccaggctt ccctcctcaa agttgtggat atgcaactgt gacggatgcc gaagcagtga 5220
ttgtccaggt gactcctcac catgtgctgg ttgatgaata cacaggagaa tgggttgatt 5280
cacagttcat caacggaaaa tgcagcaatt acatatgccc cactgtccat aactctacaa 5340
cctggcattc tgactataag gtcaaagggc tatgtgattc taacctcatt tccatggaca 5400
tcaccttctt ctcagaggac ggagagctat catccctggg aaaggagggc acagggttca 5460
gaagtaacta ctttgcttat gaaactggag gcaaggcctg caaaatgcaa tactgcaagc 5520
attggggagt cagactccca tcaggtgtct ggttcgagat ggctgataag gatctctttg 5580
ctgcagccag attccctgaa tgcccagaag ggtcaagtat ctctgctcca tctcagacct 5640
cagtggatgt aagtctaatt caggacgttg agaggatctt ggattattcc ctctgccaag 5700
aaacctggag caaaatcaga gcgggtcttc caatctctcc agtggatctc agctatcttg 5760
ctcctaaaaa cccaggaacc ggtcctgctt tcaccataat caatggtacc ctaaaatact 5820
ttgagaccag atacatcaga gtcgatattg ctgctccaat cctctcaaga atggtcggaa 5880
tgatcagtgg aactaccaca gaaagggaac tgtgggatga ctgggcacca tatgaagacg 5940
tggaaattgg acccaatgga gttctgagga ccagttcagg atataagttt cctttataca 6000
tgattggaca tggtatgttg gactccgatc ttcatcttag ctcaaaggct caggtgttcg 6060
aacatcctca cattcaagac gctgcttcgc aacttcctga tgatgagagt ttattttttg 6120
gtgatactgg gctatccaaa aatccaatcg agcttgtaga aggttggttc agtagttgga 6180
aaagctctat tgcctctttt ttctttatca tagggttaat cattggacta ttcttggttc 6240
tccgagttgg tatccatctt tgcattaaat taaagcacac caagaaaaga cagatttata 6300
cagacataga gatgaaccga cttggaaagt aactcaaatc ctgcacaaca gattcttcat 6360
gtttggacca aatcaacttg tgataccatg ctcaaagagg cctcaattat atttgagttt 6420
ttaattttta tgaaaaaaaa aaaaaaaaac ggaattcacc ccaccagtgc aggctgccta 6480
tcagaaagtg gtggctggtg tggctaatgc cctggcccac aagtatcact aagctcgctt 6540
tcttgctgtc caatttctat taaaggttcc tttgttccct aagtccaact actaaactgg 6600
gggatattat gaagggcctt gagcatctg 6629
<210> 4
<211> 22
<212> DNA
<213>Artificial synthesized ()
<400> 4
tttattcatt ggggtgaatt gc 22
<210> 5
<211> 25
<212> DNA
<213>Artificial synthesized ()
<400> 5
gacacaagct tacatgtggt accga 25
<210> 6
<211> 20
<212> DNA
<213>Artificial synthesized ()
<400> 6
gcaattcacc ccaatgaata 20
<210> 7
<211> 44
<212> DNA
<213>Artificial synthesized ()
<400> 7
tggctcgagc ggaggcggtt caaagttcac catagttttt ccac 44
<210> 8
<211> 31
<212> DNA
<213>Artificial synthesized ()
<400> 8
gacacgtcga ccacatggtg aggagtcacc t 31
Claims (10)
1. a kind of slow virus after birth glycoprotein, it is characterised in that the slow virus after birth glycoprotein is modified with member in element G upstreams
Part S;
Wherein, the element S is the auxilin element of specific recognition NK cell membrane surface proteins, and the element G is derivative
From the protein component of wild type slow virus envelope glycoprotein.
2. slow virus after birth glycoprotein according to claim 1, it is characterised in that the element S and element G pass through element
L is connected, and the element L is connection peptide;
Preferably, the element S is anti-CD56 single-chain antibodies;
Preferably, the element S is with histidine-tagged;
Preferably, the nucleotide sequence of the element S is as shown in SEQ ID NO.1;
Preferably, the element L is flexible peptide;
Preferably, the nucleotide sequence of the flexible peptide is as shown in SEQ ID NO.2;
Preferably, the element G is any one in VSV-G, RD114, BaEv or MLV or at least two combination.
A kind of 3. nucleotide sequence for encoding slow virus after birth glycoprotein as claimed in claim 1 or 2.
4. a kind of carrier, it is characterised in that the carrier includes nucleotide sequence as claimed in claim 3;
Preferably, the carrier is pMD2.G;
Preferably, the nucleotide sequence of the carrier is as shown in SEQ ID NO.3.
5. a kind of slow virus, it is characterised in that the slow virus is imported with carrier as claimed in claim 4, expression such as right
It is required that the slow virus after birth glycoprotein described in 1 or 2.
A kind of 6. method for preparing slow virus as claimed in claim 5, it is characterised in that comprise the following steps:
(1) carrier as claimed in claim 4 is built;
(2) by the carrier described in step (1) and packaging plasmid cotransfection mammalian cell, viral packaging is carried out.
7. according to the method described in claim 6, it is characterized in that, the method for step (1) described structure is will be such as claim 3
Between HindIII the and AdeI restriction enzyme sites of the nucleotide sequence insertion pMD2.G, structure obtains the carrier;
Preferably, step (2) described mammalian cell is 293T cells.
8. the method according to claim 6 or 7, it is characterised in that comprise the following steps:
(1) by between HindIII the and AdeI restriction enzyme sites of nucleotide sequence as claimed in claim 3 insertion pMD2.G, build
Obtain the carrier;
(2) by the carrier described in step (1) and packaging plasmid cotransfection 293T cells, viral packaging is carried out.
9. a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition includes slow virus as claimed in claim 1 or 2
After birth glycoprotein, nucleotide sequence as claimed in claim 3, carrier as claimed in claim 4 or as claimed in claim 5
In slow virus any one or at least two combination;
Preferably, described pharmaceutical composition further includes any one in pharmaceutically acceptable carrier, excipient or diluent
Or at least two combination.
10. a kind of pharmaceutical composition as claimed in claim 9 is used to prepare the medicine of T cell Immuno Suppressive Therapy tumour.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711481042.1A CN107936122A (en) | 2017-12-29 | 2017-12-29 | A kind of slow virus and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711481042.1A CN107936122A (en) | 2017-12-29 | 2017-12-29 | A kind of slow virus and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107936122A true CN107936122A (en) | 2018-04-20 |
Family
ID=61938030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711481042.1A Pending CN107936122A (en) | 2017-12-29 | 2017-12-29 | A kind of slow virus and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107936122A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021098686A1 (en) * | 2019-11-18 | 2021-05-27 | 深圳先进技术研究院 | Preparation method for therapeutic drug delivery system capable of crossing blood-brain barrier and specifically targeting glioma |
WO2022068837A1 (en) * | 2020-09-30 | 2022-04-07 | Sunshine Lake Pharma Co., Ltd. | Viral vectors and uses thereof |
CN116554353A (en) * | 2023-04-28 | 2023-08-08 | 北京奇迈永华生物科技有限公司 | Method for efficiently infecting human NK cells and other immune cells by pseudoviruses |
CN116814697A (en) * | 2023-06-05 | 2023-09-29 | 中国科学院水生生物研究所 | Lentivirus packaging system suitable for constructing stable transgenic cell line of carp family and application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103695470A (en) * | 2013-12-30 | 2014-04-02 | 深圳先进技术研究院 | Lentivirus recombinant expression vector/recombinant lentivirus, as well as application, host cell and preparing method thereof |
CN104910278A (en) * | 2015-05-27 | 2015-09-16 | 上海吉凯基因科技有限公司 | Lentivirus used for preparing CART cells and having characteristics of efficient transfection capacity and biological activity |
-
2017
- 2017-12-29 CN CN201711481042.1A patent/CN107936122A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103695470A (en) * | 2013-12-30 | 2014-04-02 | 深圳先进技术研究院 | Lentivirus recombinant expression vector/recombinant lentivirus, as well as application, host cell and preparing method thereof |
CN104910278A (en) * | 2015-05-27 | 2015-09-16 | 上海吉凯基因科技有限公司 | Lentivirus used for preparing CART cells and having characteristics of efficient transfection capacity and biological activity |
Non-Patent Citations (2)
Title |
---|
中国科学技术协会: "《免疫学学科发展报告(2014-2015)》", 30 April 2016, 中国科学技术出版社 * |
殷书磊 等: "CAR-NK抗肿瘤研究的现状与发展趋势", 《中国肿瘤生物治疗杂志》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021098686A1 (en) * | 2019-11-18 | 2021-05-27 | 深圳先进技术研究院 | Preparation method for therapeutic drug delivery system capable of crossing blood-brain barrier and specifically targeting glioma |
WO2022068837A1 (en) * | 2020-09-30 | 2022-04-07 | Sunshine Lake Pharma Co., Ltd. | Viral vectors and uses thereof |
CN116554353A (en) * | 2023-04-28 | 2023-08-08 | 北京奇迈永华生物科技有限公司 | Method for efficiently infecting human NK cells and other immune cells by pseudoviruses |
CN116554353B (en) * | 2023-04-28 | 2024-05-03 | 北京奇迈永华生物科技有限公司 | Method for efficiently infecting human NK cells and other immune cells by pseudoviruses |
CN116814697A (en) * | 2023-06-05 | 2023-09-29 | 中国科学院水生生物研究所 | Lentivirus packaging system suitable for constructing stable transgenic cell line of carp family and application |
CN116814697B (en) * | 2023-06-05 | 2024-03-08 | 中国科学院水生生物研究所 | Lentivirus packaging system suitable for constructing stable transgenic cell line of carp family and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102445667B1 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
CN107936122A (en) | A kind of slow virus and its preparation method and application | |
CN106544361B (en) | Mammalian cell expression vector, expression system, preparation method and application | |
CN110592108B (en) | Infectious recombinant cloning method for II-type VII-type epidemic NDV strain DHN3 | |
CN107338224A (en) | PD 1 knocks out the preparation of EGFRvIIICAR T cells | |
CN108913718A (en) | A kind of preparation method and application of the CAR-T cell of targeting EGFR v III | |
CN112481271B (en) | Transcription factor C/EBPZ for regulating and controlling formation of adipocytes and application thereof | |
CN106591371A (en) | CD16A/GPC3 double-antibody lentivirus expression vector, and construction method and application thereof | |
CN113025752B (en) | Internal reference gene, kit and detection method for PCR detection of 2019-nCoV and SARS virus | |
CN114540424A (en) | IGFBP7 muscle tissue specific knockout mouse animal model and construction method thereof | |
CN113943737A (en) | Application of chicken CTGF gene in inhibiting differentiation of chicken preadipocytes | |
CN114150001A (en) | Construction method of CRISPR/Cas9 vector for toxoplasma gondii gene editing | |
CN109652381A (en) | The CAR-T cell preparation method and application of CD133 is targeted based on base editor | |
CN107474131A (en) | One kind restructuring bovine serum albumin mature peptide and its preparation method and application | |
CN109022363A (en) | A kind of CD-133-CAR-T system constituting method based on PiggyBac carrier | |
CN110564766A (en) | Preparation method of whole genome expression vector pBR322-DHN3 | |
WO2020109314A1 (en) | Fibroblast growth factor 21 (fgf21) gene therapy | |
KR102009270B1 (en) | Recombinant foot-and-mouth disease virus expressing protective antigen of type O-Thi60 | |
CN106978432A (en) | Knock out carrier construction method and the application of chlamydomonas endogenous gene and expression alien gene | |
CN114134170A (en) | Preparation method and application of HA tag fusion expression vector | |
CN113481328B (en) | Kit for detecting GI.5 norovirus in clinical samples and special primer | |
CN113073086A (en) | African swine fever virus gene deletion strain and construction method and application thereof | |
CN112626119A (en) | Construction method of human CYP2D6 x 10 transgenic mouse model | |
CN109321602B (en) | PKD2 recombinant overexpression vector and construction method and application thereof | |
CN111663187A (en) | Staphylococcus aureus transposon sequencing library and construction method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180420 |